U.S. Pharma Industry Analysis
UpdatedSep 30, 2023
DataAggregated Company Financials
Companies328
- 7D-2.0%
- 3M-1.4%
- 1Y8.9%
- YTD-2.6%
Over the last 7 days, the Pharma industry has dropped 2.0%, driven by declines in Eli Lilly and Johnson & Johnson of 2.4% and 3.0%, respectively. In the past year, the industry has gained 8.9%. Earnings are forecast to grow by 19% annually.
Industry Valuation and Performance
Has the U.S. Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 30 Sep 2023 | US$1.7t | US$381.8b | US$43.8b | 19x | 37.8x | 4.3x |
| Mon, 28 Aug 2023 | US$1.8t | US$381.6b | US$44.1b | 20.5x | 40.2x | 4.6x |
| Wed, 26 Jul 2023 | US$1.7t | US$394.3b | US$60.5b | 18.3x | 28.5x | 4.4x |
| Fri, 23 Jun 2023 | US$1.7t | US$392.8b | US$60.1b | 19.2x | 29x | 4.4x |
| Sun, 21 May 2023 | US$1.7t | US$392.9b | US$60.5b | 19.1x | 28.5x | 4.4x |
| Tue, 18 Apr 2023 | US$1.7t | US$401.3b | US$68.5b | 17.7x | 24.3x | 4.2x |
| Thu, 16 Mar 2023 | US$1.6t | US$401.1b | US$69.3b | 15.4x | 22.4x | 3.9x |
| Sat, 11 Feb 2023 | US$1.7t | US$401.8b | US$68.8b | 17.9x | 24.1x | 4.1x |
| Mon, 09 Jan 2023 | US$1.8t | US$403.7b | US$70.7b | 17.5x | 25x | 4.4x |
| Wed, 07 Dec 2022 | US$1.8t | US$403.7b | US$70.7b | 16.7x | 24.9x | 4.4x |
| Fri, 04 Nov 2022 | US$1.7t | US$403.6b | US$71.6b | 16.1x | 23.4x | 4.2x |
| Sun, 02 Oct 2022 | US$1.6t | US$403.0b | US$71.3b | 12.4x | 21.9x | 3.9x |
| Tue, 30 Aug 2022 | US$1.6t | US$403.0b | US$70.2b | 14.6x | 22.4x | 3.9x |
| Thu, 28 Jul 2022 | US$1.7t | US$393.0b | US$63.1b | 22.8x | 26.6x | 4.3x |
| Sat, 25 Jun 2022 | US$1.7t | US$392.6b | US$64.9b | 21.7x | 25.8x | 4.3x |
| Mon, 23 May 2022 | US$1.7t | US$392.5b | US$64.7b | 20.1x | 25.8x | 4.2x |
| Wed, 20 Apr 2022 | US$1.7t | US$373.8b | US$60.9b | 21.8x | 27.5x | 4.5x |
| Fri, 18 Mar 2022 | US$1.6t | US$373.7b | US$60.2b | 20.6x | 26.9x | 4.3x |
| Sun, 13 Feb 2022 | US$1.5t | US$377.1b | US$55.5b | 21.9x | 27.9x | 4.1x |
| Tue, 11 Jan 2022 | US$1.6t | US$361.1b | US$37.8b | 24.6x | 43.6x | 4.6x |
| Thu, 09 Dec 2021 | US$1.5t | US$361.1b | US$38.1b | 21.9x | 40.6x | 4.3x |
| Sat, 06 Nov 2021 | US$1.6t | US$358.3b | US$38.6b | 21.4x | 41.1x | 4.4x |
| Mon, 04 Oct 2021 | US$1.5t | US$337.6b | US$25.8b | 20.3x | 58.3x | 4.4x |
| Wed, 01 Sep 2021 | US$1.6t | US$338.5b | US$25.8b | 19.6x | 61x | 4.7x |
| Thu, 08 Jul 2021 | US$1.5t | US$324.4b | US$20.4b | 23.4x | 73.2x | 4.6x |
| Wed, 31 Mar 2021 | US$1.4t | US$309.5b | US$16.9b | 18.8x | 83.5x | 4.5x |
| Sat, 02 Jan 2021 | US$1.4t | US$303.0b | US$18.3b | 18.8x | 75.1x | 4.5x |
| Tue, 06 Oct 2020 | US$1.3t | US$284.8b | US$25.5b | 20.6x | 50.2x | 4.5x |
Price to Earnings Ratio
50.2x
Current Industry PE
- Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 37.8x which is lower than its 3-year average PE of 42.6x.
- The industry is trading close to its 3-year average PS ratio of 4.4x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have grown 20% per year over the last three years.
- Revenues for these companies have grown 10% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.44% | |
| Healthcare | -0.89% | |
| Pharma | -1.95% | |
| Pharma | -1.95% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| PFE Pfizer | US$33.17 | 1.5% +US$2.7b | -24.2% | PE8.7x | |
| GPCR Structure Therapeutics | US$50.42 | 48.3% +US$628.4m | n/a | PB9x | |
| NMRA Neumora Therapeutics | US$14.11 | 27.9% +US$472.4m | n/a | PE-16.4x | |
| RPRX Royalty Pharma | US$27.14 | 3.1% +US$363.6m | -32.5% | PE47.8x | |
| VTRS Viatris | US$9.86 | 2.3% +US$263.9m | 15.7% | PE6.4x |
